NCT Number: NCT05020574
The most common tissue expander-related infections are from Staphylococcus and Pseudomonas species. In addition, from breast tissue microbiome studies, Staphylococcus and Pseudomonas show variable abundance across samples. The investigator hypothesizes that participants undergoing mastectomy with high initial abundance of Staphylococcus and/or Pseudomonas are more likely to develop subsequent tissue expander-related infections from these respective organisms.
Interested in participating?
Request Info18 year and older
Female
Interventional
Phase 2
San Francisco, California, 94143, United States
Location status: Recruiting
Laura Barnes, MD
CONTACT
Laura Barnes, MD
SUB_INVESTIGATOR
Merisa Piper, MD
PRINCIPAL_INVESTIGATOR
Michael Campbell, PhD
SUB_INVESTIGATOR
CONTACT
PRIMARY OBJECTIVE:
I. To determine the feasibility of breast microbiome sampling using the study techniques
SECONDARY OBJECTIVES:
I. To define the differences in the gut and breast microbiomes between participants undergoing mastectomy with implant-based reconstruction who develop post-operative implant infection and those who do not.
II. To determine the effects of post-operative antibiotics on the gut and breast microbiomes after mastectomy with implant-based reconstruction.
OUTLINE: Participants are randomized to 1 of 2 cohorts.
COHORT A: Participants receive postoperative antibiotics to take for at least 7 days post-operatively.
COHORT B: Participants receive no antibiotics post-operatively in the absence of clinical evidence of infection.
Participants are followed up for 90 days.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Given orally (PO)
Other names: Keflex
Time frame: 90 days
The feasibility of success in obtaining samples from breast tissue will be measured as a binary outcome (successful or not successful) over time (intra-operatively, week 1, week 2, week 3, and week 4). The investigators will assess and document success in obtaining a tissue sample immediately at the time of sampling of each participant.
Time frame: 90 days
The feasibility of success in obtaining samples from the tissue expander aspiration ports will be measured as a binary outcome (successful or not successful) over time (intra-operatively, week 1, week 2, week 3, and week 4). The investigators will assess and document success in obtaining a aspirate sample immediately at the time of sampling of each participant.
Time frame: 90 days
Feasibility based off of the success rates in producing microbiome data from tissue samples in each patient will be measured as a binary outcome (successful or not successful) and will be reported.
Time frame: 90 days
Feasibility based off of the success rates in producing microbiome data from tissue samples in each patient will be measured as a binary outcome (successful or not successful) and will be reported.
Time frame: 90 days
Feasibility based off of the success rates in producing microbiome data from tissue or aspirate samples in each patient will be measured as a binary outcome (successful or not successful) and will be reported.
Time frame: 90 days
The investigators will analyze the microbiomes between groups, between microbiome environments (gut v. breast, inter-individual). The correlate of change in breast microbiome over time will be compared to the total duration of antibiotics for Cohort A only. The measure of association ranges from +1 to -1, with a value of zero equal to no association.
Time frame: 90 days
Safety will be assessed by clinically assessing for signs of post-operative infection in each patient at each clinic visit. A post-operative infection is defined by clinical assessment of findings of surgical site erythema, tenderness, edema, and/or purulent drainage +/- fever. Proportion of participants with clinically diagnosed infection will be reported for each group and final diagnosis for analyses will be binary; a participant will either have a post-operative infection in the 90 day post-operative period or not have a post-operative infection in the 90 day post-operative period.
Time frame: 90 days
Alpha diversity will be evaluated for species richness by number of operational taxonomic units and for evenness using the Shannon Index. The Shannon diversity index (H) is an index that is commonly used to characterize species diversity in a community and accounts for both abundance and evenness of the species present. The proportion of species (i) relative to the total number of species (pi) is calculated, and then multiplied by the natural logarithm of this proportion (lnpi). The resulting product is summed across species, and multiplied by -1. Shannon's equitability (EH) can be calculated by dividing H by Hmax (here Hmax = lnS). Equitability assumes a value between 0 and 1 with 1 being complete evenness and the overall index score is represented by a percentage of the species.
Time frame: 90 days
The investigators will evaluate microbial composition by grouping identified microbes into operational taxonomic units at the species, genera and phyla levels and will compare the relative abundances of these microbes between groups at the species, gene
Contact information is provided by the study sponsor or research team.
University of California, San Francisco
Other
Microbiome and Association With Implant Infections: Investigating the Impact of Antibiotics on the Gut and Breast Microbiomes Post-mastectomy With Implant-based Breast Reconstruction
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05535192
Breast Cancer, Breast Cancer Female
Boston, Massachusetts, United States
View Trial DetailsNCT07198724
Breast Cancer, Breast Cancer Female
Boston, Massachusetts, United States
View Trial DetailsNCT07505797
Benign Breast Condition, Breast Cancer
Sacramento, California, United States
View Trial DetailsNCT05072314
Breast Cancer, Breast Cancer Female
Kingswood, New South Wales, Australia
View Trial Details